Amgen, Sanofi and Merck announce a string of deals at #JPM17; McDonough out at Sobi
• Amgen has tied the knot with Germany’s Immatics, paying $30 million upfront and offering hundreds of millions more in possible milestones for the development of bispecific T cell-engaging therapeutics for a range of cancers.
• Just weeks after ImmuNext signed Roche up as a partner, Sanofi has stepped on board to partner on a preclinical CD40L antibody for autoimmune disease that has potential in treating multiple sclerosis and lupus. The deal is worth a potential $500 million, though it likely starts out on the small side.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.